Studying Harms Is Key to Improving Psychedelic-Assisted Therapy-Participants Call for Changes to Research Landscape

JAMA Psychiatry. 2023 May 1;80(5):411-412. doi: 10.1001/jamapsychiatry.2023.0099.
No abstract available

Plain language summary

This Viewpoint discusses serious adverse events linked to interactions between therapists and patients in trials of psychedelic-assisted therapy.

MeSH terms

  • Hallucinogens* / adverse effects
  • Humans
  • Psilocybin
  • Psychotherapy
  • Research


  • Hallucinogens
  • Psilocybin